Inhibition of Rho-kinase protects the heart against ischemia/reperfusion injury

Cardiovascular Research

Volumn 61, Issue 3, 2004, Pages 548-558

  Bao, Weike ^a   Hu, Erding ^a   Tao, Ling ^b   Boyce, Rogely ^a   Mirabile, Rosanna ^a   Thudium, Douglas T ^a   Ma, Xin Ling ^b   Willette, Robert N ^a   Yue, Tian Li ^a  

^a GLAXOSMITHKLINE   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Apoptosis; Infarction; Ischemia; Mouse; Reperfusion

Indexed keywords

4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; CHEMOATTRACTANT; CYTOKINE; INTERLEUKIN 6; RHO KINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; CONFERENCE PAPER; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INHIBITION; HEART INFARCTION; HEART LEFT VENTRICLE CONTRACTION; KERATINOCYTE; MALE; MOUSE; MUSCLE CELL; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REPERFUSION INJURY;

AMIDES; ANIMALS; APOPTOSIS; BLOTTING, WESTERN; IMMUNOHISTOCHEMISTRY; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MICE; MICE, INBRED STRAINS; MYOCARDIAL CONTRACTION; MYOCARDIAL ISCHEMIA; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; NEUTROPHILS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS C-BCL-2; PYRIDINES;

EID: 1142297518     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cardiores.2003.12.004     Document Type: Conference Paper

References (37)

1. Verma S., Fedak P.W., Weisel R.D.et al. Fundamental of reperfusion injury for the clinical cardiologist. Circulation. 105:2002;2332-2336.
2. Ishizaki T., Maekawa M., Fujisawa K.et al. The small GTP-binding protein Rho binds to and activates a 160 kDa Ser/Thr protein kinase homologous to myotonic dystrophy kinase. EMBO J. 15:1996;1885-1893.
3. Shimokawa H. Rho-kinase as a novel therapeutic target in treatment of cardiovascular diseases. J. Cardiovasc. Pharmacol. 39:2002;319-327.
4. Narumiya S. The small GTPase Rho: cellular functions and signal transduction. J. Biochem. (Tokyo). 120:1996;215-228.
5. Utsunomiya T., Satoh S., Ikegaki I., Toshima Y., Asano T., Shimokawa H. Antianginal effects of hydroxyfasudil, a Rho-kinase inhibitor, in a canine model of effort angina. Br. J. Pharmacol. 134:2001;1724-1730.
6. Sato S., Ikegaki I., Asano T., Shimokawa H. Antiischemic properties of fasudil in experimental models of vasospastic angina. Jpn. J. Pharmacol. 87:2001;34-40.
7. Satoh S., Ueda Y., Koyanagi M.et al. Chronic inhibition of Rho kinase blunts the process of left ventricular hypertrophy leading to cardiac contractile dysfunction in hypertension-induced heart failure. J. Mol. Cell. Cardiol. 35:2003;59-70.
8. Uehata M., Ishizaki T., Satoh H.et al. Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature. 389:1997;990-994.
9. Guo Y., Jones W.K., Xuan Y.T.et al. The late phase of ischemic preconditioning is abrogated by targeted disruption of the inducible NO synthase gene. Proc. Natl. Acad. Sci. U. S. A. 96:1999;11507-11512.
10. Romanic A.M., Harrison S.M., Bao W.et al. Myocardial protection from ischemia/reperfusion injury by targeted deletion of matrix metalloproteinase-9. Cardiovasc. Res. 54:2002;549-558.
11. Yue Tl.T.L., Chen J., Bao W.et al. In vivo myocardial protection from ischemia/reperfusion injury by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone. Circulation. 104:2001;2588-2594.
12. Gao F., Gao E., Yue T.L.et al. Nitric oxide mediates the antiapoptotic effect of insulin in myocardial ischemia-reperfusion: the roles of PI3-kinase, Akt, and endothelial nitric oxide synthase phosphorylation. Circulation. 105:2002;1497-1502.
13. Zhang X.W., Liu Q., Wang Y., Thorlacius H. CXC chemokines, MIP-2 and KC, induce P-selectin-dependent neutrophil rolling and extravascular migration in vivo. Br. J. Pharmacol. 133:2001;413-421.
14. Riento K., Ridley A.J. Rocks: multifunctional kinases in cell behaviour. Nat. Rev., Mol. Cell Biol. 4(6):2003 (Jun.);446-456.
15. Kawano Y., Fukata Y., Oshiro N.et al. Phosphorylation of myosin-binding subunit (MBS) of myosin phosphatase by Rho-kinase in vivo. J. Cell Biol. 147(5):1999 (Nov. 29);1023-1038.
16. Takemoto M., Sun J., Hiroki J., Shimokawa H., Liao J.K. Rho-kinase mediates hypoxia-induced downregulation of endothelial nitric oxide synthase. Circulation. 106:2002;57-62.
17. Sah V.P., Minamisawa S., Tam S.P.et al. Cardiac-specific overexpression of RhoA results in sinus and atrioventricular nodal dysfunction and contractile failure. J. Clin. Invest. 103:1999;1627-1634.
18. Zhao Z.Q., Vinten-Johansen J. Myocardial apoptosis and ischemic preconditioning. Cardiovasc. Res. 55:2002;438-455.
19. Kang P.M., Izumo S. Apoptosis and heart failure: a critical review of the literature. Circ. Res. 86:2000;1107-1113.
20. Kajstura J., Cheng W., Reiss K.et al. Apoptotic and necrotic myocyte cell deaths are independent contributing variables of infarct size in rats. Lab. Invest. 74:1996;86-107.
21. Olivetti G., Abbi R., Quaini F.et al. Apoptosis in the failing human heart. N. Engl. J. Med. 336:1997;1131-1141.
22. Kirshenbaum L.A., de Moissac D. The bcl-2 gene product prevents programmed cell death of ventricular myocytes. Circulation. 96:1997;1580-1585.
23. Chen Z., Chua C.C., Ho Y.S., Hamdy R.C., Chua B.H. Overexpression of Bcl-2 attenuates apoptosis and protects against myocardial I/R injury in transgenic mice. Am. J. Physiol, Heart Circ. Physiol. 280:2001;H2313-H2320.
24. Maulik N., Sasaki H., Addya S., Das D.K. Regulation of cardiomyocyte apoptosis by redox-sensitive transcription factors. FEBS Lett. 485:2000;7-12.
25. Zhao Z.Q., Nakamura M., Wang N.P.et al. Reperfusion induces myocardial apoptotic cell death. Cardiovasc. Res. 45:2000;651-660.
26. Valks D.M., Kemp T.J., Clerk A. Regulation of Bcl-xL expression by H2O2 in cardiac myocytes. J. Biol. Chem. 29:2003;29.
27. Hashimoto T., Yamashita M., Ohata H., Momose K. Lysophosphatidic acid enhances in vivo infiltration and activation of guinea pig eosinophils and neutrophils via a Rho/Rho-associated protein kinase-mediated pathway. J. Pharmacol. Sci. 91:2003;8-14.
28. Niggli V. Rho-kinase in human neutrophils: a role in signalling for myosin light chain phosphorylation and cell migration. FEBS Lett. 445:1999;69-72.
29. Gwechenberger M., Mendoza L.H., Youker K.A.et al. Cardiac myocytes produce interleukin-6 in culture and in viable border zone of reperfused infarctions. Circulation. 99:1999;546-551.
30. Woldbaek P.R., Tonnessen T., Henriksen U.L.et al. Increased cardiac IL-18 mRNA, pro-IL-18 and plasma IL-18 after myocardial infarction in the mouse; a potential role in cardiac dysfunction. Cardiovasc. Res. 59(1):2003 (Jul. 1);122-131.
31. Mukai Y., Shimokawa H., Matoba T.et al. Involvement of Rho-kinase in hypertensive vascular disease: a novel therapeutic target in hypertension. FASEB J. 15(6):2001 (Apr.);1062-1064.
32. Satoh S., Utsunomiya T., Tsurui K.et al. Pharmacological profile of hydroxy fasudil as a selective rho kinase inhibitor on ischemic brain damage. Life Sci. 69:2001;1441-1453.
33. Kandabashi T., Shimokawa H., Miyata K.et al. Inhibition of myosin phosphatase by upregulated rho-kinase plays a key role for coronary artery spasm in a porcine model with interleukin-1beta. Circulation. 101:2000;1319-1323.
34. Mohri M., Shimokawa H., Hirakawa Y., Masumoto A., Takeshita A. Rho-kinase inhibition with intracoronary fasudil prevents myocardial ischemia in patients with coronary microvascular spasm. J. Am. Coll. Cardiol. 41:2003;15-19.
35. Tominaga T., Ishizaki T., Narumiya S., Barber D.L. p160ROCK mediates RhoA activation of Na-H exchange. EMBO J. 17(16):1998 (Aug. 17);4712-4722.
36. + exchange inhibitors for cardioprotective therapy: progress, problems and prospects. J. Am. Coll. Cardiol. 39(5):2002 (Mar. 6);747-753.
37. Boyce S.W., Bartels C., Bolli R.et al. Impact of sodium-hydrogen exchange inhibition by cariporide on death or myocardial infarction in high-risk CABG surgery patients: results of the CABG surgery cohort of the GUARDIAN study. J. Thorac. Cardiovasc. Surg. 126(2):2003 (Aug.);420-427.